Comparison of psoriasis and atopic dermatitis guidelines—an argument for aggressive atopic dermatitis management

Mary E. Lohman, Peter A Lio*

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The development of effective systemic treatments has revolutionized the treatment of inflammatory skin diseases. The availability of safe new treatments and the understanding of psoriasis as a systemic disease with comorbidities and effects on quality of life have driven the current aggressive treatment paradigm of psoriasis. Historically the morbidity of atopic dermatitis (AD) has been dismissed, given the perception of AD as “just” a rash. Differences in the guidelines for psoriasis and AD management may suggest variations in the current conceptualization of disease severity and effects on quality of life. Published guidelines from the American Academy of Dermatology for the management of psoriasis and AD were reviewed. We recorded the similarities and differences in disease assessment and therapy. The threshold to use biologic agents for moderate to severe psoriasis highlights the aggressive nature of modern psoriasis treatment. AD guidelines include an assessment of quality of life but do not designate a disease severity threshold for systemic treatment. AD and psoriasis have a tremendous effect on quality of life. The AD guidelines have a less aggressive approach to disease management than the psoriasis guidelines. We should think critically about rapid advancement to systemic agents in AD management, especially now that more and better agents are being developed.

Original languageEnglish (US)
Pages (from-to)739-742
Number of pages4
JournalPediatric Dermatology
Volume34
Issue number6
DOIs
StatePublished - Nov 1 2017

Fingerprint

Atopic Dermatitis
Psoriasis
Guidelines
Quality of Life
Biological Factors
Disease Management
Exanthema
Skin Diseases
Comorbidity
Morbidity

Keywords

  • atopic dermatitis
  • eczema
  • psoriasis
  • quality of life

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Dermatology

Cite this

@article{616e4ca6595245cf8168c0e5623ddf78,
title = "Comparison of psoriasis and atopic dermatitis guidelines—an argument for aggressive atopic dermatitis management",
abstract = "The development of effective systemic treatments has revolutionized the treatment of inflammatory skin diseases. The availability of safe new treatments and the understanding of psoriasis as a systemic disease with comorbidities and effects on quality of life have driven the current aggressive treatment paradigm of psoriasis. Historically the morbidity of atopic dermatitis (AD) has been dismissed, given the perception of AD as “just” a rash. Differences in the guidelines for psoriasis and AD management may suggest variations in the current conceptualization of disease severity and effects on quality of life. Published guidelines from the American Academy of Dermatology for the management of psoriasis and AD were reviewed. We recorded the similarities and differences in disease assessment and therapy. The threshold to use biologic agents for moderate to severe psoriasis highlights the aggressive nature of modern psoriasis treatment. AD guidelines include an assessment of quality of life but do not designate a disease severity threshold for systemic treatment. AD and psoriasis have a tremendous effect on quality of life. The AD guidelines have a less aggressive approach to disease management than the psoriasis guidelines. We should think critically about rapid advancement to systemic agents in AD management, especially now that more and better agents are being developed.",
keywords = "atopic dermatitis, eczema, psoriasis, quality of life",
author = "Lohman, {Mary E.} and Lio, {Peter A}",
year = "2017",
month = "11",
day = "1",
doi = "10.1111/pde.13282",
language = "English (US)",
volume = "34",
pages = "739--742",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "6",

}

Comparison of psoriasis and atopic dermatitis guidelines—an argument for aggressive atopic dermatitis management. / Lohman, Mary E.; Lio, Peter A.

In: Pediatric Dermatology, Vol. 34, No. 6, 01.11.2017, p. 739-742.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of psoriasis and atopic dermatitis guidelines—an argument for aggressive atopic dermatitis management

AU - Lohman, Mary E.

AU - Lio, Peter A

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The development of effective systemic treatments has revolutionized the treatment of inflammatory skin diseases. The availability of safe new treatments and the understanding of psoriasis as a systemic disease with comorbidities and effects on quality of life have driven the current aggressive treatment paradigm of psoriasis. Historically the morbidity of atopic dermatitis (AD) has been dismissed, given the perception of AD as “just” a rash. Differences in the guidelines for psoriasis and AD management may suggest variations in the current conceptualization of disease severity and effects on quality of life. Published guidelines from the American Academy of Dermatology for the management of psoriasis and AD were reviewed. We recorded the similarities and differences in disease assessment and therapy. The threshold to use biologic agents for moderate to severe psoriasis highlights the aggressive nature of modern psoriasis treatment. AD guidelines include an assessment of quality of life but do not designate a disease severity threshold for systemic treatment. AD and psoriasis have a tremendous effect on quality of life. The AD guidelines have a less aggressive approach to disease management than the psoriasis guidelines. We should think critically about rapid advancement to systemic agents in AD management, especially now that more and better agents are being developed.

AB - The development of effective systemic treatments has revolutionized the treatment of inflammatory skin diseases. The availability of safe new treatments and the understanding of psoriasis as a systemic disease with comorbidities and effects on quality of life have driven the current aggressive treatment paradigm of psoriasis. Historically the morbidity of atopic dermatitis (AD) has been dismissed, given the perception of AD as “just” a rash. Differences in the guidelines for psoriasis and AD management may suggest variations in the current conceptualization of disease severity and effects on quality of life. Published guidelines from the American Academy of Dermatology for the management of psoriasis and AD were reviewed. We recorded the similarities and differences in disease assessment and therapy. The threshold to use biologic agents for moderate to severe psoriasis highlights the aggressive nature of modern psoriasis treatment. AD guidelines include an assessment of quality of life but do not designate a disease severity threshold for systemic treatment. AD and psoriasis have a tremendous effect on quality of life. The AD guidelines have a less aggressive approach to disease management than the psoriasis guidelines. We should think critically about rapid advancement to systemic agents in AD management, especially now that more and better agents are being developed.

KW - atopic dermatitis

KW - eczema

KW - psoriasis

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=85033975525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033975525&partnerID=8YFLogxK

U2 - 10.1111/pde.13282

DO - 10.1111/pde.13282

M3 - Article

VL - 34

SP - 739

EP - 742

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 6

ER -